Drug candidate identification


Forward and reverse discovery processes identify cellular therapeutic targets and generate a pool of small molecule hits and peptide hits. Strategy for hit to lead optimization depends on targets type, administration route, SMEs and virus-derived peptides. When SMEs are already available, a drug repurposing strategy associated with new intellectual property strategy is preferred to accelerate clinical development and value.